Form 4: CytomX CSO Marcia Belvin Boosts Stake with New Equity Awards

CytomX Therapeutics' SVP and Chief Scientific Officer, Marcia Belvin, reported the acquisition of 60,000 restricted stock units and 250,000 stock options.

Summary

• Marcia Belvin, SVP, Chief Scientific Officer of CytomX Therapeutics, Inc. (CTMX), acquired 60,000 Restricted Stock Units (RSUs) on February 2, 2026.
• Each RSU entitles the reporting person to receive one share of Common Stock upon vesting, with a price of $0.
• The RSUs vest annually in 1/3rd increments on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, contingent on continued service.
• Following this transaction, Marcia Belvin beneficially owns 332,252 shares of Common Stock, which includes 218,958 RSUs.
• Additionally, Marcia Belvin acquired 250,000 stock options on February 2, 2026, with an exercise price of $6.09.
• These stock options vest monthly in 1/48th increments from February 2, 2026, becoming fully vested and exercisable on the fourth anniversary of this date, subject to continued service.
• The stock options have an expiration date of February 1, 2036.
• Following this transaction, Marcia Belvin beneficially owns 250,000 derivative securities in the form of stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal for executive retention and alignment of interests, as a key scientific officer is receiving significant equity awards tied to future performance.

Positives

• The grant of 60,000 Restricted Stock Units and 250,000 stock options to a key executive like the SVP, Chief Scientific Officer, aligns management's interests with long-term shareholder value.
• Equity awards serve as a strong incentive for executive retention and continued dedication to the company's scientific and strategic goals.

Future Outlook

The equity awards, with their multi-year vesting schedules, imply an expectation of continued service from the SVP, Chief Scientific Officer, through the vesting periods, aligning her future with the company's long-term success.

Industry Context

StockSavvy.ai notes that equity awards, including a mix of restricted stock units and stock options, are a standard and widely adopted practice within the biotechnology industry. These compensation structures are crucial for attracting, retaining, and motivating top scientific and executive talent, ensuring their interests are aligned with the company's long-term research and development objectives and overall shareholder value creation.

Comparison to Industry Standards

• Equity compensation packages for senior scientific officers in the biotechnology sector commonly include a combination of RSUs and stock options, typically with multi-year vesting schedules to ensure retention and performance alignment.
• For example, similar grants are observed at established biotech firms like Amgen or Gilead Sciences for their R&D leadership, although the specific values and vesting terms can vary based on the company's stage of development, market capitalization, and the individual's role and contribution.

Related Party Transactions

• The acquisition of 60,000 Restricted Stock Units and 250,000 Stock Options by Marcia Belvin, a Senior Vice President and Chief Scientific Officer, constitutes a related party transaction as it involves compensation from the issuer to an executive officer.

Stakeholder Impact

• Shareholders: The equity awards align the interests of a key executive with those of shareholders, potentially fostering long-term value creation.
• Employees: This type of compensation reinforces standard practices for executive incentives within the company and the industry.

Next Steps

• Continued service by Marcia Belvin to CytomX Therapeutics, Inc. is required for the vesting of both the Restricted Stock Units and the Stock Options.

Key Dates

Recommendation

This Form 4 filing primarily details executive compensation through equity awards, which is a routine event for publicly traded companies. While it signals continued commitment from a key executive, it does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

CytomX Therapeutics, CTMX, Marcia Belvin, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, Biotechnology